Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01490736 | Phase 1/2 Sequentially Staged Safety Study in Healthy Subjects and Subjects With Mild Acne | PHASE1 | COMPLETED | 129 | — | — | Dec 1, 2011 | Jun 1, 2013 | Jul 20, 2021 | 1 | Canada |
| Arm | Type | Description |
|---|---|---|
| LTS/Vehicle | EXPERIMENTAL | Within subject control study |
| Name | Type | Description |
|---|---|---|
| Lemuteporfin | DRUG | lemuteporfin topical solution, 1% |
Inclusion Criteria: * Stage 1 only: healthy subjects * Stage 1-4: male or female subjects age 18 years or older * Stage 2: subjects with sebum excretion rate of 4 or higher on forehead * Stage 2-4: subjects with at least 2 inflammatory acne lesions on the forehead * Stage 3-4: subjects with sebum e...